These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 26342718

  • 1. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.
    Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M, Scagliotti GV.
    Cancer Treat Rev; 2015 Dec; 41(10):884-92. PubMed ID: 26342718
    [Abstract] [Full Text] [Related]

  • 2. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
    Attard G, Antonarakis ES.
    Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988
    [No Abstract] [Full Text] [Related]

  • 3. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
    Nakazawa M, Antonarakis ES, Luo J.
    Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254
    [Abstract] [Full Text] [Related]

  • 4. Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).
    Penning TM.
    J Steroid Biochem Mol Biol; 2015 Sep; 153():105-13. PubMed ID: 26032458
    [Abstract] [Full Text] [Related]

  • 5. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB.
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [Abstract] [Full Text] [Related]

  • 6. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Lolli C, De Lisi D, Conteduca V, Gurioli G, Scarpi E, Schepisi G, Ravaglia G, Menna C, Farolfi A, Altavilla A, Burgio SL, Tonini G, Santini D, De Giorgi U.
    Prostate; 2019 Aug; 79(11):1211-1220. PubMed ID: 31251826
    [Abstract] [Full Text] [Related]

  • 7. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
    Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, Silberstein JL, Taylor MN, Maughan BL, Denmeade SR, Pienta KJ, Paller CJ, Carducci MA, Eisenberger MA, Luo J.
    J Clin Oncol; 2017 Jul 01; 35(19):2149-2156. PubMed ID: 28384066
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Moll JM, Hofland J, Teubel WJ, de Ridder CMA, Taylor AE, Graeser R, Arlt W, Jenster GW, van Weerden WM.
    Prostate; 2022 Apr 01; 82(5):505-516. PubMed ID: 35037287
    [Abstract] [Full Text] [Related]

  • 10. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
    Isaacsson Velho P, Fu W, Wang H, Mirkheshti N, Qazi F, Lima FAS, Shaukat F, Carducci MA, Denmeade SR, Paller CJ, Markowski MC, Marshall CH, Eisenberger MA, Antonarakis ES.
    Eur Urol; 2020 Jan 01; 77(1):14-21. PubMed ID: 31176623
    [Abstract] [Full Text] [Related]

  • 11. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
    van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.
    Eur J Cancer; 2013 Dec 01; 49(18):3821-30. PubMed ID: 24200698
    [Abstract] [Full Text] [Related]

  • 12. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Welti J, Rodrigues DN, Sharp A, Sun S, Lorente D, Riisnaes R, Figueiredo I, Zafeiriou Z, Rescigno P, de Bono JS, Plymate SR.
    Eur Urol; 2016 Oct 01; 70(4):599-608. PubMed ID: 27117751
    [Abstract] [Full Text] [Related]

  • 13. Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?
    Antonarakis ES.
    Expert Rev Anticancer Ther; 2015 Feb 01; 15(2):143-5. PubMed ID: 25547524
    [Abstract] [Full Text] [Related]

  • 14. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
    Graham L, Schweizer MT.
    Med Oncol; 2016 May 01; 33(5):44. PubMed ID: 27042852
    [Abstract] [Full Text] [Related]

  • 15. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
    van Soest RJ, de Morrée ES, Kweldam CF, de Ridder CMA, Wiemer EAC, Mathijssen RHJ, de Wit R, van Weerden WM.
    Eur Urol; 2015 Jun 01; 67(6):981-985. PubMed ID: 25484141
    [Abstract] [Full Text] [Related]

  • 16. Androgen pathway resistance in prostate cancer and therapeutic implications.
    Maughan BL, Antonarakis ES.
    Expert Opin Pharmacother; 2015 Jun 01; 16(10):1521-37. PubMed ID: 26067250
    [Abstract] [Full Text] [Related]

  • 17. Emerging mechanisms of enzalutamide resistance in prostate cancer.
    Claessens F, Helsen C, Prekovic S, Van den Broeck T, Spans L, Van Poppel H, Joniau S.
    Nat Rev Urol; 2014 Dec 01; 11(12):712-6. PubMed ID: 25224448
    [Abstract] [Full Text] [Related]

  • 18. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
    Hung J, Taylor AR, Divine GW, Hafron JM, Hwang C.
    Clin Genitourin Cancer; 2016 Oct 01; 14(5):381-388. PubMed ID: 27157640
    [Abstract] [Full Text] [Related]

  • 19. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Bernemann C, Schnoeller TJ, Luedeke M, Steinestel K, Boegemann M, Schrader AJ, Steinestel J.
    Eur Urol; 2017 Jan 01; 71(1):1-3. PubMed ID: 27471164
    [Abstract] [Full Text] [Related]

  • 20. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
    Okegawa T, Ninomiya N, Masuda K, Nakamura Y, Tambo M, Nutahara K.
    Prostate; 2018 Jun 01; 78(8):576-582. PubMed ID: 29508425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.